Delcath Systems Inc (DCTH)

[JJAAMMAANN]

I agree that soothing needs to happen to get the PPS headed north, but I don't rule out the possibility of a partnership or out right buy out. Currently Delcath has three ongoing studies registered with NIH on the clinical trials website. Positive results on any one or all three of these studies can be a game changer for Delcath. Add in the fact that the FDA is working with Delcath to relax the protocol for enrollment and possible study completion dates...and that safety data had already been looked at by the "Independent Data Monitoring Committee". I would think, and this is just me thinking here...something big will be announced as soon as the balance sheets are cleaned up and the company patents are released! There have been several smaller biotechs bought out over the past year, and I see the chances of Delcath to be no different.
IMHO
Best of luck!

1. Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy https://clinicaltrials.gov/ct2/show/NCT03266042?term=Delcath&rank=2

Study Start Date : January 14, 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : February 2019

2. Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT02415036?term=Delcath&rank=3

Study Start Date : June 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : February 2018

3. Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)
https://clinicaltrials.gov/ct2/show/NCT02678572?term=Delcath&rank=4

Study Start Date : January 2015
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019